Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study

INTRODUCTION: We investigated the mechanisms of the glucose-lowering effects of teneligliptin and canagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, by monitoring several gastrointestinal peptides using the most appropriate measuring methods during multiple meal tolerance tests (MTTs...

Descripción completa

Detalles Bibliográficos
Autores principales: Noda, Tomoho, Ebihara, Emi, Ueno, Hiroaki, Sadohara, Keisuke, Tanaka, Yuri, Nagatomo, Yuuma, Murakami, Yousuke, Yonamine, Shinichi, Tsuchimochi, Wakaba, Sakoda, Hideyuki, Yamaguchi, Hideki, Nakazato, Masamitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778556/
https://www.ncbi.nlm.nih.gov/pubmed/31300948
http://dx.doi.org/10.1007/s13300-019-0666-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778556/
https://www.ncbi.nlm.nih.gov/pubmed/31300948
http://dx.doi.org/10.1007/s13300-019-0666-7

Ejemplares similares